US EditionTop 10 drugs by patent volume: How biologics build ‘platform empires’ while small molecule create ‘patent thickets’
Summary by Research & Development World
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Top 10 drugs by patent volume: How biologics build ‘platform empires’ while small molecule create ‘patent thickets’
Why does Roche’s oncology blockbuster Herceptin (trastuzumab) have 1,536 patents in a comprehensive search of international patents but only 393 when searching for patent titles? This four-fold difference is a window into pharmaceutical strategy. For complex biologics, especially monoclonal antibodies, the platform product strategy is gaining ground. Popularized in part by Humira (adalimumab), which is… The post Top 10 drugs by patent volume: Ho…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium